

FUND FACTSHEET

EDENTREE AMITY GLOBAL EQUITY FUND FOR CHARITIES

SHARE CLASS A

April 2018



Investment Objective

The Fund's primary objective is to deliver longer term capital appreciation and an income from a portfolio of global equities. The Fund seeks to primarily invest in a diversified portfolio of equities of UK and international companies which make a positive contribution to society and the environment through sustainable and socially responsible practises.

Fund Manager

Manager name:	Ketan Patel
Start Date:	07/07/2015
Manager name:	David Osfield
Start Date:	01/09/2016

Price Information

Single price:	123.50p (as at 31/03/2018)
Currency:	British Pound
Pricing:	Daily
Historic Yield (%)*:	3.39

Fund Facts

Fund Size:	£11.21m
IA Sector:	Unclassified
Index:	FTSE World
Asset Class:	Equity
Launch Date:	04/04/2011
Domicile:	United Kingdom
Number of Holdings:	54
Minimum Investment:	£1,000

Identifiers

Sedol:	B45M5W5
ISIN:	GB00B45M5W55

Dividends

Ex-Dividend Date:	01/01, 01/04, 01/07, 01/10
Dividend Pay Date:	28/02, 31/05, 31/08, 30/11

Charges

AMC†:	0.55%
Ongoing Charge:	0.77%
Initial Charge:	0.00%

Fund Manager Commentary

Global equity markets ended the quarter in negative territory after reaching all-time highs at the start of the year. Market volatility rose on the back of escalating tensions over global trade, increasing turmoil in the White House and a major slide in the tech sector. The overweight position in the UK aided performance via stock selection, whilst the overweight exposure to Europe hindered performance. The underweight positions to the USA and Asia Pacific, including Japan, were positive for the fund. At a sector level, overweight positions in Healthcare and Basic Materials added to performance, whilst the overweight position in Financials and the underweight in Consumer Goods & Services held back performance. Portfolio activity included trimming the positions in Cisco Systems, Victrex and Abbvie on the back of strong share price performance. The small position in Aris Bioscience was topped up with the company in the midst of a capital raise. At a stock level, positive contributors to fund performance included Bioventix which had excellent final results, Smurfit Kappa which was subject to bid rumours and GlaxoSmithKline which bought out the consumer JV with Novartis, removing a key concern over the dividend. Detractors included Abbvie, AXA and Mears Group.

Cumulative Performance (as at 31/03/2018)



Amity Global Equity Fund for Charities

Cumulative Performance (as at 31/03/2018)

	1m	3m	6m	1y	3y	5y	10y
Fund	-4.41%	-4.63%	-2.15%	2.64%	24.15%	43.11%	-

Discrete Performance (as at 31/12/2017)

	31/12/2012 to 31/12/2013	31/12/2013 to 31/12/2014	31/12/2014 to 31/12/2015	31/12/2015 to 31/12/2016	31/12/2016 to 31/12/2017
Fund	14.67%	8.41%	1.43%	18.22%	15.32%

Source: FE. Fund and Sector performance is shown in local currency, on a bid to bid basis with income re-invested into the fund.

Top 10 Holdings

Name	%
BIOVENTIX PLC	4.33%
CISCO SYSTEMS INC	3.81%
ASR NEDERLAND NV	3.54%
MICROSOFT CORP	3.49%
TAIWAN SEMICONDUCTOR-SP ADR	3.21%
PFIZER INC	3.17%
VICTREX PLC	2.98%
LYONDELLBASELL INDU-CL A	2.69%
ING GROEP NV	2.68%
ABBVIE INC	2.56%

Ratings and Awards

FE Crown Rating:



Contact Information

EdenTree Investment Management

PO Box 3733

Swindon

SN4 4BG

Investment professionals – 0800 011 3821


Private individuals – 0800 358 3010

Charity fund enquiries – 0800 032 3778

www.edentreeim.com

From 1 January 2018 the Amity Global Equity Income Fund for Charities became the Amity Global Equity Fund for Charities, following minor changes to the fund's name, investment objective and investment policy.

Capitalisation of Assets



Sector Breakdown



Region Breakdown



Asset Breakdown

